Promising results from clinical trials with interleukin-1 (IL-1) antagonists, TNF-α inhibitors, and blockade of IL-6 and IL-17 pathways [19–21] opened the door for anticytokine strategies in the treatment of T2D. This evidence concerns the gene IL1B and type 2 diabetes mellitus.